Related Experiment Video

Updated: Nov 19, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib

Marios Papadimitriou1, Christos A Papadimitriou2

  • 1Oncology Unit, Second Department of Surgery, "Aretaieion" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.

Anticancer Research
|January 31, 2021
PubMed

Insights

Metastatic colorectal cancer (mCRC) progression involves VEGF and EGFR pathways. Antiangiogenic therapies targeting VEGF/VEGFR signaling, like regorafenib, show efficacy in treating mCRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Metastatic colorectal cancer (mCRC) progression is driven by key signaling pathways, including vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
  • An imbalance favoring pro-angiogenesis (angiogenic switch) occurs early in colorectal cancer (CRC) development, promoting neovascularization and tumor progression.
  • VEGF-A is a critical cytokine in CRC angiogenesis, tumor growth, and metastasis.

Purpose of the Study:

  • To review the role of antiangiogenic tyrosine kinase inhibitors (TKIs) in mCRC treatment.
  • To highlight the efficacy of regorafenib as a targeted therapy for mCRC.

Main Methods:

  • Review of scientific literature on angiogenesis in CRC.
  • Analysis of clinical data for antiangiogenic agents targeting VEGF/VEGFR signaling.
  • Focus on tyrosine kinase inhibitors (TKIs) including regorafenib.

Main Results:

  • VEGF/VEGFR signaling is a crucial target in mCRC therapy.
  • Approved antiangiogenic agents demonstrate significant efficacy in mCRC treatment.
  • Regorafenib is an effective antiangiogenic TKI for mCRC.

Conclusions:

  • Targeting VEGF/VEGFR signaling is a validated strategy for mCRC.
  • Antiangiogenic TKIs, particularly regorafenib, represent important therapeutic options for patients with mCRC.
Keywords:
Metastatic colorectal cancerVEGFVEGFRangiogenesisanti-angiogenic tyrosine kinase inhibitors (TKIs)regorafenibreview

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K